PKU is an autosomal recessive inborn error of metabolism caused by loss-of-function mutations in the PAH gene, which encodes the hepatic enzyme phenylalanine hydroxylase. PAH catalyzes the irreversible hydroxylation of L-phenylalanine to L-tyrosine using tetrahydrobiopterin (BH4) as a cofactor. More than 560 disease-causing mutations across the N-terminal regulatory domain, central catalytic domain, and C-terminal tetramerization domain of PAH have been cited, with the catalytic region reported as the most frequently affected site.

Phenylalanine ammonia-lyase (PAL) is a plant- and prokaryote-derived enzyme that metabolizes Phe to trans-cinnamic acid and ammonia without requiring BH4 cofactor activity — a mechanistic advantage over direct PAH replacement strategies. BioMarin Pharmaceutical holds the most extensive patent coverage for PAL variants engineered for enhanced phenylalanine-converting activity and reduced immunogenicity, with the primary PAL source being Anabaena variabilis (AvPAL). Key engineering strategies include cysteine-to-serine substitutions at positions 503 and/or 565, and optimization of PEGylation to extend half-life.

Synlogic Operating Company uses genetically engineered bacteria (primarily Escherichia coli Nissle 1917 derivatives) programmed to express PAL, phenylalanine transporters, and optionally L-amino acid deaminase (LAAD) under inducible promoter control. The strategy aims to degrade dietary Phe in the gastrointestinal tract, circumventing systemic immunogenicity challenges of injectable PEG-PAL. Target reductions of blood Phe levels by at least 20–50% from baseline after administration are cited in retrieved filings.

Three distinct assignees appear in the patent dataset pursuing mRNA-based PAH restoration: Shire Human Genetic Therapies, Inc. (now part of Takeda), Moderna TX, Inc., and Arcturus Therapeutics, Inc. All approaches encode human PAH or functional fragments thereof in mRNA formulated for lipid nanoparticle (LNP) or liposomal delivery to hepatocytes. Shire/Takeda filings report preclinical proof-of-concept in PAH-knockout mouse models, demonstrating that PAH mRNA can reduce serum phenylalanine levels to wild-type levels within 6 hours of dosing.

Gene therapy via rAAV vectors encoding codon-optimized human PAH under liver-specific promoter/enhancer control is addressed by four assignees: Genzyme Corporation, the Trustees of the University of Pennsylvania, Takeda Pharmaceutical Company (via an rAAV8 capsid approach), and Generation Bio Company (closed-end DNA vectors). Genzyme filings describe PAH variant polypeptides engineered for greater stability and catalytic activity, with amino acid substitutions at positions M180, K199, S250, and G256. Generation Bio's ceDNA platform represents a non-viral, capsid-free alternative potentially addressing AAV immunogenicity and manufacturing scalability constraints.

PKU ranks among the most common inborn errors of metabolism globally, occurring at approximately 1:3,000 births, with approximately 13,000 patients in the United States affected. Dissatisfaction with the burdens of lifelong dietary restriction and the limitations of existing enzyme substitution approaches have accelerated innovation. Even well-treated patients may exhibit neurocognitive and neuropsychiatric deficits. PEGylated recombinant PAL (PEG-PAL) administered by injection produces injection-site reactions and anti-drug antibodies in most subjects, representing a key unmet need.